Low-grade serous ovarian cancer (LGSOC)
Low-grade serous ovarian cancer is a slow-growing, RAS-driven type of ovarian cancer that resists chemotherapy but responds to hormone blockers and MEK-pathway drugs.
About 5-10% of serous ovarian cancers; younger patients, KRAS/BRAF/NRAS mutations in ~30-50%, wild-type TP53, strong ER expression, low proliferation. Chemotherapy response rates are under 25%; endocrine therapy and MEK/RAF pathway inhibition (trametinib in GOG 281; avutometinib + defactinib, approved 2025) are the mainstays. Contrast with high-grade serous carcinoma.
Pages like this
not linked directly; found by shared links- CompanyVerastem Oncology
Shares RAMP 201, Avutometinib + defactinib, RAS / RAF / MEK / ERK (MAPK), KRAS.
- IdeaTurn a brake back on: drugs that reactivate the PP2A phosphatase
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- PathwayHippo–YAP/TAZ
Shares Invasion: proteases, adhesion & the invasive front, RAS / RAF / MEK / ERK (MAPK), KRAS.
- PairingG12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- ProductMRTX1133
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- ProductElironrasib
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- CompanyQuanta Therapeutics
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
- CompanyFrontier Medicines
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.